Based on the results of COLUMBUS trial, a phase III study of 577 patients with metastatic or unresectable melanoma harboring BRAFV600E mutation, the combination of encorafenib and binimetinib (a BRAF inhibitor) was approved by FAD in June 2018. The gene discussed is BRAF; the disease is melanoma.